BioCentury | Jul 1, 2020
Emerging Company Profile

With potential for re-dosing, Carmine’s gene therapy tech attracts Takeda as partner

Carmine is developing red blood cell-based vesicles to deliver gene therapies, offering immunogenicity and manufacturing advantages over viral vector systems. The platform, which offers the potential for re-dosable gene therapies, led Takeda to become Carmine’s...
BioCentury | Jun 30, 2020
Product Development

Second death in Audentes gene therapy trial may highlight need for more careful dosing

The report of a second patient death in a trial of an AAV8-based gene therapy from Audentes and Astellas renewed decades-old concerns over the modality’s safety, but the adverse events may reflect a need for...
BioCentury | Jun 26, 2020
Finance

June 25 Quick Takes: Chi-Med rakes in $100M; plus bank rules rolled back, newco DeCART has June ties and more

Chi-Med raises $100M private placement  Hutchison China MediTech Ltd. (NASDAQ:HCM; LSE:HCM) raised $100 million Thursday in a private placement to General Atlantic through the sale of 4 million ADSs at $25. The price matches its...
BioCentury | Jun 26, 2020
Deals

Sosei Heptares gains new GPCR discovery partner in AbbVie

Sosei Heptares’ GPCR-targeting platform is continuing to draw attention from pharma with a deal with AbbVie that follows 2019 discovery collaborations with Genentech and Takeda. The Sosei Group Corp. (Tokyo:4565) unit will use its StaR...
BioCentury | Jun 26, 2020
Product Development

Gilead goes for lung delivery of remdesivir, earlier COVID-19 disease stage

As European approval of IV remdesivir fast approaches, Gilead said it will begin evaluating an inhaled formulation of the antiviral drug -- a path that could take it out of the hospital. The move comes...
BioCentury | Jun 20, 2020
Management Tracks

Nurix bolsters leadership; plus Lynch named Xilio chairman, Edgewise, BioXCel, Catabasis, Catalyst and more

Nurix Therapeutics Inc. has announced a slew of leadership changes including Gwenn Hansen’s promotion to CSO from SVP of research, and Hans van Houte’s promotion to CFO from SVP of finance. The targeted protein degradation...
BioCentury | Jun 19, 2020
Product Development

Finch’s microbiome therapy clears bar in pivotal C. diff readout

A pivotal Phase II readout for Finch’s microbiome treatment for recurrent Clostridium difficile infection paves the way for a Phase III trial that will further test the therapy in a broad population for which the...
BioCentury | Jun 19, 2020
Product Development

BEATing COVID-19 from home

As knowledge regarding the natural history of COVID-19 continues to evolve, biopharmas are looking to real-world data generated from the BEAT19 initiative to inform clinical trial design for COVID-19 therapies. Behavior, Environment and Treatments for...
BioCentury | Jun 17, 2020
Product Development

June 16 Quick Takes: Takeda out-licenses neurology pipeline to Neurocrine; plus Illumina challenge blocks BGI, FDA approves a pair of firsts and more

Takeda receives $120M up front for seven neurology therapies  Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) granted Neurocrine Biosciences Inc. (NASDAQ:NBIX) an exclusive, worldwide license to seven neurology programs: three mood disorder therapies that have completed...
BioCentury | Jun 17, 2020
Politics, Policy & Law

COVAX created to try to avoid global bidding frenzy for COVID-19 vaccines

Panic buying of vaccines by high income countries, mopping up supply and squeezing out lower income countries, is the nightmare postscript to COVID-19 that international health agencies envisage could play out if steps aren’t taken...
Items per page:
1 - 10 of 3741
BioCentury | Jul 1, 2020
Emerging Company Profile

With potential for re-dosing, Carmine’s gene therapy tech attracts Takeda as partner

Carmine is developing red blood cell-based vesicles to deliver gene therapies, offering immunogenicity and manufacturing advantages over viral vector systems. The platform, which offers the potential for re-dosable gene therapies, led Takeda to become Carmine’s...
BioCentury | Jun 30, 2020
Product Development

Second death in Audentes gene therapy trial may highlight need for more careful dosing

The report of a second patient death in a trial of an AAV8-based gene therapy from Audentes and Astellas renewed decades-old concerns over the modality’s safety, but the adverse events may reflect a need for...
BioCentury | Jun 26, 2020
Finance

June 25 Quick Takes: Chi-Med rakes in $100M; plus bank rules rolled back, newco DeCART has June ties and more

Chi-Med raises $100M private placement  Hutchison China MediTech Ltd. (NASDAQ:HCM; LSE:HCM) raised $100 million Thursday in a private placement to General Atlantic through the sale of 4 million ADSs at $25. The price matches its...
BioCentury | Jun 26, 2020
Deals

Sosei Heptares gains new GPCR discovery partner in AbbVie

Sosei Heptares’ GPCR-targeting platform is continuing to draw attention from pharma with a deal with AbbVie that follows 2019 discovery collaborations with Genentech and Takeda. The Sosei Group Corp. (Tokyo:4565) unit will use its StaR...
BioCentury | Jun 26, 2020
Product Development

Gilead goes for lung delivery of remdesivir, earlier COVID-19 disease stage

As European approval of IV remdesivir fast approaches, Gilead said it will begin evaluating an inhaled formulation of the antiviral drug -- a path that could take it out of the hospital. The move comes...
BioCentury | Jun 20, 2020
Management Tracks

Nurix bolsters leadership; plus Lynch named Xilio chairman, Edgewise, BioXCel, Catabasis, Catalyst and more

Nurix Therapeutics Inc. has announced a slew of leadership changes including Gwenn Hansen’s promotion to CSO from SVP of research, and Hans van Houte’s promotion to CFO from SVP of finance. The targeted protein degradation...
BioCentury | Jun 19, 2020
Product Development

Finch’s microbiome therapy clears bar in pivotal C. diff readout

A pivotal Phase II readout for Finch’s microbiome treatment for recurrent Clostridium difficile infection paves the way for a Phase III trial that will further test the therapy in a broad population for which the...
BioCentury | Jun 19, 2020
Product Development

BEATing COVID-19 from home

As knowledge regarding the natural history of COVID-19 continues to evolve, biopharmas are looking to real-world data generated from the BEAT19 initiative to inform clinical trial design for COVID-19 therapies. Behavior, Environment and Treatments for...
BioCentury | Jun 17, 2020
Product Development

June 16 Quick Takes: Takeda out-licenses neurology pipeline to Neurocrine; plus Illumina challenge blocks BGI, FDA approves a pair of firsts and more

Takeda receives $120M up front for seven neurology therapies  Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) granted Neurocrine Biosciences Inc. (NASDAQ:NBIX) an exclusive, worldwide license to seven neurology programs: three mood disorder therapies that have completed...
BioCentury | Jun 17, 2020
Politics, Policy & Law

COVAX created to try to avoid global bidding frenzy for COVID-19 vaccines

Panic buying of vaccines by high income countries, mopping up supply and squeezing out lower income countries, is the nightmare postscript to COVID-19 that international health agencies envisage could play out if steps aren’t taken...
Items per page:
1 - 10 of 3741